Shift in brain metabolism in late onset Alzheimer’s disease: Implications for biomarkers and therapeutic interventions
Open accessThe DOI matches its Crossref record; 49 of the 49 references it cites were found in a registry or an index.
Abstract
Alzheimer’s is a neurodegenerative disease with a complex and progressive pathological phenotype characterized first by hypometabolism and impaired mitochondrial bioenergetics followed by pathological burden. Increasing evidence indicates an antecedent and potentially causal role of mitochondrial bioenergetic deficits and brain hypometabolism coupled with increased mitochondrial oxidative stress in AD pathogenesis. Compromised mitochondrial bioenergetics lead to over-production and mitochondrial accumulation of β-amyloid coupled with oxidative stress to cause a shift in brain metabolic profile from glucose-driven bioenergetics towards a compensatory, but less efficient, ketogenic pathway. We propose that the compensatory shift from a primarily aerobic glycolysis pathway to a ketogenic/fatty acid β-oxidation pathway eventually leads to white matter degeneration. The essential role of mitochondrial bioenergetics and the unique trajectory of compensatory metabolic adaptations in brain enable a bioenergetic-centric strategy for development of biomarkers to detect the bioenergetic shift in brain to enable early identification of people at risk for developing AD. From a therapeutic perspective, this unique trajectory of alterations in brain metabolic capacity enable disease-stage specific strategies targeting brain metabolism for disease prevention and treatment. A combination of nutraceutical and pharmaceutical intervention that enhances glucose-driven metabolic activity and potentiates mitochondrial bioenergetic function could prevent the antecedent decline in brain glucose metabolism, promote healthy aging and prevent AD. Alternatively, during the prodromal incipient phase of AD, sustained activation of ketogenic metabolic pathways coupled with supplement of the alternative fuel source, ketone bodies, can sustain mitochondrial bioenergetic function to prevent or delay further progression of the disease.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Alzheimer's disease: the amyloid cascade hypothesis
Hardy, J. A., & Higgins, G. A. (1992) · Science · doi:10.1126/science.1566067 · Cited by 7,484 · cited 1×
“…the deposition of Ab initiates a cascade of events, including the formation of NFTs, prolonged inflammatory responses, increased oxidative stress and mitochondrial dysfunction, which eventually lead to cell death and dementia (Armstrong, 2011; Hardy, 2006; Hardy and Higgins, 1992; Sommer, 2002).”
BackgroundSperling, R. A., Aisen, P. S., Beckett, L. A., Bennett, D. A., Craft, S., Fagan, A. M., Iwatsubo, T., Jack, C. R., Kaye, J., Montine, T. J., et al. (2011) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2011.03.003 · Cited by 7,155 · cited 1×
“Recently the clinical phases of AD have been expanded to include presymptomatic AD, during which time an individual appears cognitively normal but is beginning to exhibit some of the pathological changes of AD (Sperling et al., 2011).”
BackgroundMitochondrial Dysfunction and Oxidative Stress in Neurodegenerative Diseases
Lin, M. T., & Beal, M. F. (2006) · Nature · doi:10.1038/nature05292 · Cited by 6,455 · cited 1×
“As the major source for cellular reactive oxygen species, mitochondria generate free radicals (superoxide anion, O2 ) and hydrogen peroxide (H2O2) as by-products of oxidative phosphorylation (Dumont et al., 2010; Lin and Beal, 2006).”
BackgroundHypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade
Jack, C. R., Knopman, D. S., Jagust, W. J., Shaw, L. M., Aisen, P. S., Weiner, M. W., Petersen, R. C., & Trojanowski, J. Q. (2010) · The Lancet Neurology · doi:10.1016/s1474-4422(09)70299-6 · Cited by 4,806 · cited 5×
“CSF levels of both total tau and p-tau are increased, likely due to degenerating neurons releasing these proteins into the CSF (Jack et al., 2010).”
BackgroundInfluentialOxidative Damage Is the Earliest Event in Alzheimer Disease
Nunomura, A., Perry, G., Aliev, G., Hirai, K., Takeda, A., Balraj, E. K., Jones, P. K., Ghanbari, H., Wataya, T., Shimohama, S., et al. (2001) · Journal of Neuropathology & Experimental Neurology · doi:10.1093/jnen/60.8.759 · Cited by 1,885 · cited 2×
“Interestingly, an increase in oxidative stress has been demonstrated to increase b-amyloid production in vitro and in vivo (Li et al., 2004; Moreira et al., 2007; Nunomura et al., 2001).”
BackgroundHansson, O., Zetterberg, H., Buchhave, P., Londos, E., Blennow, K., & Minthon, L. (2006) · The Lancet Neurology · doi:10.1016/s1474-4422(06)70355-6 · Cited by 1,700 · cited 3×
“All rights reserved. acology and Pharmaceutical Sciences, University of Southern California, School of Pharmacy, Los 436; fax: +1 323 442 1470. exponentially with age in people 65 or older (Hansson et al., 2006).”
BackgroundInfluentialABAD Directly Links Aß to Mitochondrial Toxicity in Alzheimer's Disease
Lustbader, J. W., Cirilli, M., Lin, C., Xu, H. W., Takuma, K., Wang, N., Caspersen, C., Chen, X., Pollak, S., Chaney, M., et al. (2004) · Science · doi:10.1126/science.1091230 · Cited by 1,303
Manczak, M., Anekonda, T. S., Henson, E., Park, B. S., Quinn, J., & Reddy, P. H. (2006) · Human Molecular Genetics · doi:10.1093/hmg/ddl066 · Cited by 1,104 · cited 4×
“Mitochondrial dysfunction results in a series of changes that contribute to Aβ accumulation in mitochondria, including impaired oxidative phosphorylation, uncoupled electron transport chain, compromised ATP synthase, and COX inhibition (Manczak et al., 2006; Readnower et al., 2011; Young and Bennett, 2010).”
BackgroundInfluential[ 11 C]PIB in a nondemented population: Potential antecedent marker of Alzheimer disease
Mintun, M. A., LaRossa, G. N., Sheline, Y. I., Dence, C. S., Lee, S. Y., Mach, R. H., Klunk, W. E., Mathis, C. A., DeKosky, S. T., & Morris, J. C. (2006) · Neurology · doi:10.1212/01.wnl.0000228230.26044.a4 · Cited by 1,036 · cited 2×
“…phase was particularly important for explaining why some individuals have no cognitive deficits but, upon autopsy, amyloid plaques and neurofibrillary tangles are present in the brain (De Meyer et al., 2010; Jack et al., 2008; Knopman et al., 2003; Mintun et al., 2006; Price and Morris, 1999).”
BackgroundFunctional brain abnormalities in young adults at genetic risk for late-onset Alzheimer's dementia
Reiman, E. M., Chen, K., Alexander, G. E., Caselli, R. J., Bandy, D., Osborne, D., Saunders, A. M., & Hardy, J. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2635903100 · Cited by 977 · cited 5×
“…antecedent abnormality in cerebral glucose utilization decades prior to the onset of AD, particularly in the hippocampal and entorhinal cortical regions (de Leon et al., 2001; Ishii et al., 1997; Mosconi et al., 2008, 2009a; Reiman et al., 2004; Rosenbloom et al., 2011; Spulber et al., 2008).”
BackgroundInfluential
Cited by
Age, APOE and sex: triad of risk of Alzheimer’s disease.
Riedel, B. C., Thompson, P. M., & Brinton, R. D. (2016) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/j.jsbmb.2016.03.012 · Cited by 627
Self-citationPerimenopause as a neurological transition state
Brinton, R. D., Yao, J., Yin, F., Mack, W. J., & Cadenas, E. (2015) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2015.82 · Cited by 612
Self-citationEstrogen: A master regulator of bioenergetic systems in the brain and body
Rettberg, J. R., Yao, J., & Brinton, R. D. (2014) · Frontiers in Neuroendocrinology · doi:10.1016/j.yfrne.2013.08.001 · Cited by 534
Self-citationTrushina, E., Dutta, T., Persson, X.-M. T., Mielke, M. M., & Petersen, R. C. (2013) · PLoS ONE · doi:10.1371/journal.pone.0063644 · Cited by 438
Ketogenic Diet in Alzheimer’s Disease
Rusek, M., Pluta, R., Ułamek-Kozioł, M., & Czuczwar, S. J. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20163892 · Cited by 319
Metadata
- Authors
- Yao, J., Rettberg, J. R., Klosinski, L. P., Cadenas, E., & Brinton, R. D.
- Venue
- Molecular Aspects of Medicine
- Publisher
- Elsevier BV
- Published
- 2011-08
- Volume
- 32
- Issue
- 4-6
- Pages
- 247-257
- ISSN
- 0098-2997 (ISSN-L)
- OpenAlex
- W2129437576
- Cited by
- 123
- References
- 49
- FWCI
- 5.78
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Shift in brain metabolism in late onset Alzheimer’s disease: Implications for biomarkers and therapeutic interventions. https://app.cochat.ai/papers/10.1016/j.mam.2011.10.005
- The paper
- Yao, J., Rettberg, J. R., Klosinski, L. P., Cadenas, E., & Brinton, R. D. (2011). Shift in brain metabolism in late onset Alzheimer’s disease: Implications for biomarkers and therapeutic interventions. Molecular Aspects of Medicine. https://doi.org/10.1016/j.mam.2011.10.005
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.